Impella use in real-world cardiogenic shock patients: Sobering outcomes
Open Access
- 26 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2), e0247667
- https://doi.org/10.1371/journal.pone.0247667
Abstract
Critically ill patients with cardiogenic shock could benefit from ventricular assist device support using the Impella microaxial blood pump. However, recent studies suggested Impella not to improve outcomes. We, therefore, evaluated outcomes and predictors in a real-world scenario. In this retrospective single-center trial, 125 patients suffering from cardiac arrest/cardiogenic shock between 2008 and 2018 were analyzed. 93 Patients had a prior successful cardiopulmonary resuscitation. The primary endpoint was hospital mortality. Associations of covariates with the primary endpoint were assessed by univariable and multivariable logistic regression. Adjusted odds ratios (aOR) and optimal cut-offs (using Youden index) were obtained. Hospital mortality was high (81%). Baseline lactate was 4.7mmol/L [IQR = 7.1mmol/L]. In multivariable logistic regression, only age (aOR 1.13 95%CI 1.06–1.20; p3.3mmol/L and age >66 years. Patients were retrospectively stratified into three risk groups: Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years and lactate >3.3mmol/L (high-risk, n = 51). Risk of death increased from 41% in the low-risk group, to 79% in the medium risk group and 100% in the high-risk group. The predictive abilities of this model were high (AUC 0.84; 95% 0.77–0.92). Mortality was high in this real-world collective of severely ill cardiogenic shock patients. Better patient selection is warranted to avoid unethical use of Impella. Age and lactate might help to improve patient selection.This publication has 15 references indexed in Scilit:
- Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shockJournal of Critical Care, 2017
- Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insightExpert Review of Medical Devices, 2017
- The Lactate/Albumin Ratio: A Valuable Tool for Risk Stratification in Septic Patients Admitted to ICUInternational Journal of Molecular Sciences, 2017
- Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2016
- Retrospective analysis of circulatory support with the Impella CP® device in patients with therapy refractory cardiogenic shockInternational Journal of Cardiology, 2016
- Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user groupInternational Journal of Cardiology, 2015
- Incidence and prognosis of vascular complications after percutaneous placement of left ventricular assist deviceJournal of Vascular Surgery, 2015
- Mechanical Circulatory Devices in Acute Heart FailureCritical Care Clinics, 2014
- The Impella Device for Acute Mechanical Circulatory Support in Patients in Cardiogenic ShockThe Annals of Thoracic Surgery, 2014
- Percutaneous Left-Ventricular Support With the Impella-2.5–Assist Device in Acute Cardiogenic ShockCirculation: Heart Failure, 2013